



Economic and Social Council

Distr.: General
8 February 2021

Original: English

2021 session

23 July 2020–22 July 2021

Agenda item 4

Elections, nominations, confirmations and appointments

Election of two members of the International Narcotics Control Board from among candidates nominated by the World Health Organization

Note by the Secretary-General

1. The present note contains information on candidates nominated by the World Health Organization (WHO) for election to the International Narcotics Control Board. Information on candidates nominated by Governments is contained in documents [E/2021/9/Add.7](#) and [E/2021/9/Add.8](#).
2. In accordance with established procedure, the Secretary-General invited the Director General of WHO to submit a list of candidates for election to membership in the International Narcotics Control Board for the period from 2022 to 2027 on the expiration of the term of office of two members of the Board nominated by WHO. The posts are currently occupied by Cornelis de Joncheere (Netherlands) and Richard Phillip Mattick (Australia).
3. As at 18 January 2021, five candidates had been proposed by WHO. Their names are listed below in alphabetical order:

Sawitri Assanangkornchai	Thailand
Cornelis de Joncheere	Netherlands
Custódia das Dores Isaac Mandlhate	Mozambique
Richard Phillip Mattick	Australia
Olayinka Olusola Omigbodun	Nigeria
4. The biographical information that was transmitted with the proposals for candidatures is contained in the annex to the present note.
5. In accordance with article 9, paragraph 2, of the Single Convention on Narcotic Drugs of 1961,¹ as amended by the 1972 Protocol,² members of the Board shall not hold any position or engage in any activity that would be liable to impair their

¹ United Nations, *Treaty Series*, vol. 520, No. 7515.

² *Ibid.*, vol. 976, No. 14152.



impartiality in the exercise of their functions. The positions and activities of the following persons are, in particular, incompatible with membership on the Board: persons who hold government posts, are in paid service of their Governments or are acting under instructions from their Governments; persons who represent a Government at national or international forums on drug-related issues; and persons who are engaged in any activity, whether private or public, that would be liable to impair their impartiality in the exercise of their functions on the Board or whose activity is in conflict with the functions of the Board.

6. Document [E/2021/9/Add.7](#) contains information on meetings of the Board in 2020, payments made to members and the present membership (annex I); the texts of articles 9 (Composition and functions of the Board) and 10 (Terms of office and remuneration of members of the Board) of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, as well as that of article 20 (Transitional provisions) of the 1972 Protocol (annex II); information on qualifications and other conditions of membership on the Board (annex III); and a list of the States parties to the Single Convention as amended by the 1972 Protocol, the Convention on Psychotropic Substances of 1971³ and the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988⁴ (annex IV).

³ Ibid., vol. 1019, No. 14956.

⁴ Ibid., vol. 1582, No. 27627.

Annex

Biographical information on candidates for election to the International Narcotics Control Board*

Sawitri Assanangkornchai (Thailand)

Education

Ph.D. (Medicine), University of Sydney, Australia (2000); M. Med. Sc. (Clinical Epidemiology), University of Newcastle, Australia (1995); Dipl. Board Psychiatry, Siriraj Hospital, Mahidol University, Thailand (1985); Graduate in Medicine, Prince of Songkla University, Thailand (1981).

Present posts

Professor of Psychiatry, Epidemiology Unit, Faculty of Medicine, Prince of Songkhla University, Hat Yai, Songkhla, Thailand; Director, Centre for Addiction Studies and Centre for Alcohol Studies, Thai Health Promotion Foundation; Vice President, Academic Committee on Substance Abuse Network, Office of the Narcotics Control Board, Ministry of Justice; Member, Subcommittee for academic affairs and Subcommittee for treatment and rehabilitation of the National Alcohol Control Committee; Member, Steering Committee for the Stop-Drink Network, Thai Health Promotion Foundation and Steering Committee for Alcohol and Tobacco Control of the Department of Disease Control, Ministry of Public Health; President, Asia-Pacific Society on Alcohol and Addiction Research (APSAAR); Member, Membership Committee and Academic Committee, International Society on Biomedical Research on Alcohol (ISBRA); Member, WHO Working Group on Classification of Substance-Related and Addictive Disorders for the Revision of ICD-10 Mental and Behavioural Disorders, WHO TAG on Alcohol and Drug epidemiology.

Publications

Scopus: <https://www.scopus.com/authid/detail.uri?authorId=6603003749>

PubMed: <https://pubmed.ncbi.nlm.nih.gov/?term=Assanangkornchai+S&sort=date>

Research gate: https://www.researchgate.net/profile/Sawitri_Assanangkornchai

Google scholar: <https://scholar.google.com/citations?user=VqjeWK8AAAAJ&hl=en>

* Curricula vitae are issued without formal editing.

Cornelis de Joncheere (Netherlands)

Education

Doctor of Pharmacy (Pharm. D) (Apothekersexamen, license as professional pharmacist), University of Amsterdam, the Netherlands (1980–1981); Master of Business Administration (MBA), National University, San Diego, California, United States of America/San Jose, Costa Rica; Bachelor of Science (B.Sc) (cum laude/honorary student) and Master of Science (M.Sc), Pharmacy, State University Groningen, the Netherlands (1972–1979).

Present posts

President, INCB (2019–2020 and 2020–2021); Member, INCB 2017–2022; Chair, Netherlands Antibiotics Development Platform (www.nadp.nl); Member, Scientific Advisory Panel, Medicines Patent Pool, Geneva (<http://www.medicinespatentpool.org>); Member, Advisory Group, Utrecht University Center for Affordable Biologicals, Netherlands; consultant on pharmaceutical policies and public health.

Previous posts

Consultant, WHO Europe, on pharmaceutical policies (2017–2020); Teacher, University of Heidelberg, Germany, and University of Nottingham, UK (2017–2020); Director, Department of Essential Medicines and Health Products at WHO (2012–2016); WHO Representative, Kiev, Ukraine (2011–2012); WHO Regional Adviser for Pharmaceuticals and Health Technologies, WHO Regional Office for Europe, Copenhagen, Denmark (1996–2010); National Essential Drugs Programme Coordinator, Pan American Health Organization/World Health Organization (PAHO/WHO), Brazil (1994–1996); Pharmacist, Essential Drugs Projects Coordinator (PAHO/WHO), Costa Rica (1988–1993); Pharmaceutical expert (PAHO/WHO) Panama (1986–1988); Pharmaceutical supply expert in Yemen Arab Republic, Ministry of Foreign Affairs, Directorate for International Cooperation, the Netherlands (1982–1985); Hospital and Community Pharmacy in Amsterdam, the Netherlands (1981–1982).

Selected memberships

President of the WHO/Europe Staff Association (2006–2010); Member of the WHO Guidelines Review Committee (2007–2011); Member of the National Institute for Health and Clinical Excellence International Advisory group, United Kingdom (since 2009); Member of the Royal Dutch Pharmaceutical Society and the International Pharmaceutical Federation; Observer to the Council of Europe European Directorate for the Quality of Medicines Pharmaceutical Experts Committee; Drug Information Association; European Society of Clinical Pharmacy; United States Pharmacopeia; International Society of Drug Bulletins; European Drug Utilization Research Group; International Society for Pharmacoepidemiology; International Society for Pharmacoeconomics and Outcomes Research; European Generic Medicines Association.

Selected publications

Lukas Radbruch, *Felicia Marie Knaul, Liliana de Lima, Cornelis de Joncheere, Afsan Bhadelia: “The key role of palliative care in response to the COVID-19 tsunami of suffering”, *The Lancet* (2020), 395, 1467–1469; Vogler, S., Zimmermann, N., de Joncheere, K.: “Policy interventions related to medicines: survey of measures in European countries 2010–2015”, *Health Policy* (2016); Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., et al.: “Prices, Costs, and

Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis,” *PLoS Med* 13(5) (2016); Leopold, C., Mantel-Teeuwisse, A.K., Vogler, S., Valkova, S., de Joncheere, K., Leufkens, H.G.M., Wagner, A., Ross-Degnan, D., Laing, R.: “Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries”, In: *Bulletin of the World Health Organization* 2014; Leopold, C., Mantel-Teeuwisse A.K., Vogler, S., de Joncheere, K., Laing, R.O., Leufkens, H.G.M.: “Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries”, in *Health Policy* vol 112 (2013), pp. 209–16; Leopold, C., Vogler, S., Mantel-Teeuwisse, A., de Joncheere, K., Leufkens, H.G.M., Laing, R., “Differences in external price referencing in Europe – a descriptive overview”, in: *Health Policy* vol. 104 (2012). p. 1; Leopold, C., Mantel-Teeuwisse, A.K., Seyfang, L., Vogler, S., de Joncheere, K., Laing, R.O., Leufkens, H.G.M., “Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries”, in *Southern Med Review*, vol. 5, No. 2 (2012), pp. 34–41; Vogler, S., Zimmermann, N., Leopold, C., de Joncheere, K., “Pharmaceutical policies in European countries in response to the global financial crisis”, In: *Southern Med Review*, Vol. 4 (2011), pp. 22–32; Kees de Joncheere, Gerald Gartlehner, Laragh Gallogly, Pertti Mustajoki, Govin Permanand, “Health information for patients and the general public”, produced by the German Institute for Quality and Efficiency in Health Care: a review by the World Health Organization (2008/2009)”; Irina Eramova, Kees de Joncheere, Ulrich Laukamm-Josten, Luis Mendao, Signe Rotberga, Maria Skarphedinsdottir, Roger Drew (WHO, Regional Office for Europe, April 2010), “Evaluation of the access to HIV/AIDS treatment and care in Lithuania”; “Review of the pharmaceutical sector with a view to developing a national medicines policy in Estonia” (WHO/EURO, May 2009); Kees de Joncheere, Irina Eramova, Jenni Kehler, Ulrich Laukamm-Josten, Signe Rotberga, Anna Zakowicz and Roger Drew “Evaluation of the access to HIV/AIDS treatment and care in Latvia”(WHO/EURO, May 2009); “Control of medicines promotion in Central European countries” (WHO/EURO, November 2008); “The Clinical Guideline programme of the National Institute for Health and Clinical Excellence” (May 2006), a review by WHO, WHO # 5063284 (May 2006); “Technology Appraisal programme of the National Institute of Clinical Excellence”, a review by WHO, WHO #5045738 (July 2003); Walley, T., Mossialos E.A., de Joncheere C.P., “Supply and regulation of medicines” (2005), *British Medical Journal*, vol. 331 (2005), pp. 171–172; Kees de Joncheere, “Alternatives to the fourth hurdle: Clinical and cost-effectiveness analyses in Europe”, *ISPOR Connections* (15 August, 2005), Vol 11, no 4; Monique Mrazek, Kees de Joncheere, Guenka Petrova, Elias Mossialos, “The pharmaceutical sector and regulation in the countries of central and eastern Europe”; in *Regulating Pharmaceuticals in Europe*, ed. Elias Mossialos, Monique Mrazek, Tom Walley (Open University Press, Berkshire, United Kingdom, 2004), ISBN 0 335 21465, pp. 323–334.

Selected meetings attended

Member of the Organizing Committee of the European Conference on Medicines Pricing and Reimbursement, Vienna (2011–2015); Member of the Organizing Committee of the International Conference on Improving Use of Medicines, 2012; Meetings for the Inter-Governmental Working Group on Public Health, Innovation and Intellectual Property, as established by WHA 59.24, and WHO/PHI (2006 to 2011); Meeting of the Intergovernmental working group on SSFFC medicines 2011; International Conference on Harmonization; London School of Economics executive courses on pharmaceutical pricing and reimbursement in Europe (1996–1998); European Union meetings (Pharmaceutical Forum and G10 Meetings, Italian, Dutch (2004), Portuguese (2007) and Czech (2009) European Union presidency meetings, Bangemann round table conferences on the single market in pharmaceuticals (1996–1998).

Custódia das Dores Isaac Mandlhate (Mozambique)**Education**

Doctorate Degree, University of Lausanne, Switzerland; Post-graduate in Psychiatry and Psychotherapy, Switzerland; Diploma in Medicine, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

Present post

Since retirement from WHO (2016), independent consultant.

Previous posts

WHO Country Representative in Zambia, during the process of recruiting the substantive WHO Representative (2017). Provided support in the different cooperation programmes, finalized WHO Country Cooperation Strategy 2017–2021 with a strategic agenda that promotes health systems and strengthens country capacity to respond to communicable diseases and to noncommunicable diseases, including mental health disorders and substance abuse (as per NCD Brazzaville Declaration of April 2014).

WHO Country Representative in Kenya (2012 to 2016). Managed team of 65 staff, contributed to the strengthening of health systems and supported the country in the transition from centralized governance to devolution as per the Kenyan new Constitution. Developed under her leadership the third generation of WHO Country Strategy (2014–2019) and the mental health policy for Kenya. Led the timely response when the country imported polio in 2013, leading to stopping the circulation of the virus in less than 2 months. Established, under her leadership, a state-of-the-art Emergency Operating Center (EOC), at the occasion of the Ebola virus outbreak in West Africa. Participated actively in the United Nations Country Team and other partnerships frameworks (Development Partners forum -DPHK-); the Coordination mechanisms for Global Fund for HIV, TB and Malaria; National Ebola Task Force among others.

WHO Country Representative in Zimbabwe (2007–2012). Contributed to the strengthening of the national health strategies, plans and programmes. Supported the country in its response to public health challenges such as cholera, polio, measles and other communicable diseases. Promoted the concept of health promotion and social and health determinants as an efficient way to tackle diseases through addressing risk factors, strengthened the Mental Health and Prevention of Substance Program at country level, encouraged the Government to ratify the Framework Convention of Tobacco Control FCTC; promoted cross-border activities; used all available opportunities to advocate for putting health in the centre of the national development agenda, in the context of the achievement of the health-related MDGs. Involved in humanitarian response, for example, to unprecedented cholera outbreak in 2008. With WHO as health cluster lead agency, active member of the United Nations Country Team (UNCT) and strong advocate of coordinated and strategic partnerships.

WHO Country Representative in Namibia (2003–2007). Contributed actively to strengthening the health system, addressed unusual polio outbreak, contributed to the prompt response with a strong advocacy for cross-border collaboration, developed, under her leadership, the first mental health policy and other policy documents.

WHO Regional Advisor for Mental Health and Prevention of Substance Abuse, Regional Office for Africa, Brazzaville (1997–2003). Contributed to advising 46 countries of the region on different global initiatives such as: the Global Campaign Against Epilepsy, the Global Campaign on Prevention of Substance Abuse in Young

People, the elaboration of the World Health Report 2001 devoted to mental health, the first Mental Health Regional Strategy for the African Region, the WHO Mental health Atlas Project and the WHO Global Mental Health Policy Project. Visited several countries of the WHO African Region and coordinated several bilateral and sub-regional meetings to discuss mental health and prevention of substance abuse.

National Mental Health Director; Director of the National Referral Psychiatric Hospital; Lecturer at Eduardo Mondlane University in Maputo; Chair of the Public Health Association; different managerial positions at District and Provincial level in Mozambique (1989–2003).

Honours

Award from Director General of WHO for response to polio outbreak in Kenya in 2013; Award from Director General of WHO as best team leader for excellent response to cholera outbreak in Zimbabwe in 2008.

Selected meetings attended

Organized, hosted, coordinated and attended a number of meetings, workshops, and conferences involving several countries of the African Region and beyond, for example: 8th Global Meeting of Heads of WHO Offices in Countries, Territories and Areas with the Director General and Regional Directors, Geneva (2015) (as speaker on behalf of all WHO Heads of Agencies); 7th Biennial Conference of the Africa Christian Health Associations Platform, Nairobi (2015) (key note speaker); Seminar on Improving Access to and Appropriate use of Medicines for Mental Disorders, Global Health Platform, Praia (2017) (chair of discussion on selection of psychotropic medicines); XVI Jornadas Nacionais de Saude (National Health Days), Maputo (2018) (presenting in plenary the theme “Suicide in Young People as a Public Health Concern”); visits to several countries of the region in support to mental health and prevention of substance abuse, strengthening health systems and reinforcing WHO country cooperation strategies.

Richard Phillip Mattick (Australia)

Education

Bachelor of Science, Honours Class 1; Master of Psychology (Clinical); Certificate in Neuroanatomy; Doctor of Philosophy.

Present posts

Honorary Professor, National Drug and Alcohol Research Centre, and Honorary Professor, Brain Sciences, UNSW, Australia; INCB Member 2015–2017 and 2017–2022.

Previous posts

Honorary professor, National Drug and Alcohol Research Centre, UNSW, Australia (2018); Professor, Brain Sciences, UNSW, Australia (2009–2017); Executive Director, Professor, National Drug and Alcohol Research Centre, Faculty of Medicine, UNSW (2002–2009); Acting Executive Director, Associate Professor and Director of Research, National Drug and Alcohol Research Centre, UNSW (2000–2002); Acting Executive Director, Associate Professor and Director of Research, National Drug and Alcohol Research Centre, UNSW (1996–2000); Director of Research, Associate Professor, National Drug and Alcohol Research Centre, UNSW (1995–1996).

Selected memberships

Member, Australian National Council on Drugs (ANCD), 2004–2007, advising the Prime Minister; invited for reappointment from 2008–2010; Member, National Expert Advisory Committee on Illicit Drugs (2002–2004); Member, Ministerial Council on Drug Strategy Working Party on Performance and Image Enhancing Drugs (2003–2005); Member, National Expert Advisory on Sustained Release Naltrexone (2002–2004); Member, Monitoring Committee of the Medically Supervised Injecting Centre, NSW Government Cabinet Office, New South Wales (2003–2004); Member, New South Wales Expert Advisory Group on Drugs and Alcohol, advising the NSW Minister of Health (2004–2007 and 2008–2013).

Selected publications

McLaren, J.A., Silins, E., Hutchinson, D., Mattick, R.P., Hall, W., “Assessing evidence for a causal link between cannabis and psychosis”, *International Journal of Drug Policy*, 21 (2010), 10–19; Larney, S., Gowing, L., Mattick, R.P., Farrell, M., Hall, W., & Degenhardt, L., “A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence”, *Drug and Alcohol Review*, 33(2), 115–128; Larance, B., Lintzeris, N., Ali, R., Dietze, P., Jenkinson, R., White, N., Mattick, R.P. and Degenhardt, L., “The diversion and injection of a buprenorphine-naloxone soluble film formulation”, *Drug and Alcohol Dependence*, 136(1) (2014), 21–27; Campbell, G., Mattick, R., Bruno, R., Larance, B., Nielsen, S., Cohen, M., Lintzeris, N., Shand, F., Hall, W., Hoban, B., Kehler, C., Farrell, M. and Degenhardt, L., “Cohort protocol: The Pain and Opioids IN Treatment (POINT) study”, *BMC Pharmacology and Toxicology* (2014); Clare, P., Bradford, D., Courtney, R., Martire, K. and Mattick, R.P. “The relationship between socioeconomic status and ‘hardcore’ smoking over time-greater accumulation of hardened smokers in low-SES than high-SES smokers”, *Tobacco Control* 2014; Larney, S., Leung, J., Grebely, J., Hickman, M., Vickerman, P., Mattick, R.P., Degenhardt, L., “The Pain and Opioids IN Treatment (POINT) study: A cohort using opioids to manage chronic non-cancer pain.” *Pain* (2020); Hines, L.A., Mattick, R.P., Michael Lynskey, “Global

systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence”, *International Journal of Drug Policy*, 77, 102656; (2020). Hines, L.A., Mattick, R.P., Lynskey, M., “Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis”, *Lancet Global Health*, 8, (1), e76–e91.

Honours

Australian Government NHMRC Principal Fellow 2013 to 2017, and re-awarded 2019 to 2023.

Selected meetings attended

Member, WHO/UNODC Technical Guidelines on Opioid Pharmacotherapies, Guidelines Development Group 2004–2008.

Member, Australian Delegation to the United Nations, Commission on Narcotic Drugs, Vienna, Austria, 13–14 March, 2007.

Member, Australian Delegation to the United Nations, Commission on Narcotic Drugs, Vienna, Austria, 6–14 March, 2008.

Olayinka Olusola Omigbodun (Nigeria)

Education

Master of Public Health (MPH) (with distinction) (Leeds); Diploma in Psychology (Manchester); Bachelor of Medicine and Surgery (Ibadan); Fellow of the Medical College of Psychiatry (Nigeria), Fellow of the West African College of Physicians.

Present posts

Professor and Head, Department of Psychiatry, College of Medicine, University of Ibadan (UI) and University College Hospital, Ibadan, Nigeria; Director, Centre for Child and Adolescent Mental Health, UI, Nigeria;

Member, International Advisory Board, The Lancet Child and Adolescent Health; Member, Lancet Commission on Global Mental Health.

Previous posts

Selected policy and technical advisory positions: Guideline Development Group on the essential package for mental, neurological and substance use disorders, to review the draft of WHO's Mental Health Gap (mhGAP) Intervention Guide (2009); Temporary Advisor to the World Health Organization (WHO) for an inter-country workshop on evaluation of psychoactive substance use disorder treatment for six countries in the African region which was held in Harare, Zimbabwe (2002 and 2003); Trainings of field workers for the National Epidemiologic survey on the use of psychoactive substances in Nigeria (2001); Training of peer educators on drug abuse and HIV/AIDS, Ibadan, Nigeria (2000).

Selected grants led and managed as Principal Investigator (since 2008): Building Child and Adolescent Mental Health Capacity in West Africa (The John D. and Catherine T. MacArthur Foundation awarded a grant to the University of Ibadan); Improving Child Mental Health Service Utilization in Ibadan Nigeria Using a Community Based Participatory Research Approach (Howard University, USA); Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents (Northwestern University, USA); Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria (NIH/Fogarty International Center); Psychological consequences of female genital cutting (World Health Organization); Needs assessment for planning maternal mental health demonstration project in Nigeria (World Health Organization).

President, International Association for Child and Adolescent Psychiatry and Allied Professions (2010 to 2014).

Pioneer Chair, African Association for Child and Adolescent Mental Health (2007–2014).

Selected publications

Full list at: https://scholar.google.com/citations?user=Ql_z47kAAAAJ&hl=en

Akinbote, J. A., Omigbodun O. O. (2018) Psychoactive Substance Use among Adolescents in Ado-Ekiti, Nigeria: Prevalence and Association with Anxiety and Depression. *International Journal of Innovative Research in Medical Science (IJIRMS)*, Volume 03, Issue 02, ISSN No. 2455–8737; Lund C., Brooke-Sumner C., Baingana F., Baron E., C, Breuer E, Chandra P., Haushofer J., Herrman H., Jordans M., Kieling C., Medina-Mora M.E., Morgan E., Omigbodun O., Tol W., Patel P., Saxena S.: Social determinants of mental disorders and the Sustainable Development Goals: a systematic review of reviews, *The Lancet Psychiatry* 2018, 5 (4), 357–369; Yusuf O.B.,

Akinyemi J. O., Adedokun B.O., Omigbodun O.O., Propensity score methodology in estimating the effect of drug use on violent behaviour among students in Southwest Nigeria, *Nigerian Journal of Psychiatry*, Volume 12 (2014), No. 2: 2–7; Abdulmalik J., Omigbodun O., Wakil M.A., Baida O., Comorbidity of Depression with Substance use among High School Students in Northern Nigeria, *Seishin Shinkeigaku Zasshi (Addiction)*, Volume 5 (2013), SS421-SS426; Dua T., Barbui C., Clark N., Fleischmann A., Poznyak V., van Ommeren M., Yasamy M.T., Ayuso-Mateos J.L., Birbeck G.L., Drummond C., Freeman M., Giannakopoulos P., Levav I., Isidore O.S., Omigbodun O., Patel V., Phillips M., Prince M., Rahimi-Movaghar A., Rahman A., Sander J.W., Saunders J.B., Servili C., Rangaswamy T., Unützer J., Ventevogel P., Vijayakumar L., Thornicroft G., Saxena S., Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations, *PLoS Medicine*, Volume 8 (2011), No. 11: 1–11; Kieling C., Baker-Henningham H., Belfer M., Conti G., Ertem I., Omigbodun O., Rohde L.A., Srinath S., Ulkuer N., Rahman A., Global child and adolescent mental health: evidence for action, *The Lancet* Volume 378 (2011), No. 9801, 1515–1525; Abdulmalik J., Omigbodun O., Beida O., Adedokun B., Psychoactive substance use among children in informal religious schools (Almajiris) in northern Nigeria, *Mental Health, Religion & Culture*, Volume 12 (2009), No. 6, 527–542; Odejide A.O., Omigbodun O., Ajuwon A., Makanjuola B.A., Bamgboye A., Oshiname F. Focus group results: Nigeria. In M. Martinic & F. Measham (Eds.), *Swimming with Crocodiles: The Culture of Extreme Drinking*, New York: Routledge (2008), Chapter 5, pp. 120–131; Omigbodun O. O., Babalola O., Psychosocial dynamics of psychoactive substance misuse among Nigerian adolescents, *Annals of African Medicine*, Volume 3 (2004), No 3. 111–115.

Honours

Selected recognitions: 2nd Prize for Poster Presentation (for work on depression in rural adolescents) out of a total of 430 posters at the 16th International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) Congress, Berlin (2004); John D. and Catherine T. MacArthur Foundation Staff Development Fellowship Award for study in Child and adolescent Mental Health, Greenwood Institute of Child Health, University of Leicester, School of Medicine, Leicester (2004); The John Griffiths Prize for Distinctive work in the course of obtaining a Masters in Public Health (MPH), awarded by the Nuffield Institute for Health (International Division), University of Leeds, Leeds, United Kingdom (September 1999).

Selected meetings attended

Health, Safety, Security and Environment Forum in the Oil and Gas Industry, Lagos, Nigeria (2018) (presentation on substance use disorders and mental health); Adolescent Mental Health, International Center for Research on Women (New York, United States, 2017); Psychosocial Support for All Children (REPSSI), Victoria Falls, Zimbabwe (2015); Pacifica Study Group, promoting the development of effective and sustainable Child and Adolescent Mental Health (CAMH) within the Pacific Region (Melbourne, Australia, 2013); Two-day Round Table on Adolescent Mental Health, UNICEF, WHO, George Washington University Center for Global Health (Washington D.C., 2011); International Advisory Group for the World Health Organization (WHO) Revision of ICD-10 Mental and Behavioural Disorders: Working Group on the Classification of Mental and Behavioural Disorders in Children and Adolescents (2010); World Health Organization Regional Office for the Eastern Mediterranean, Inter-Country Meeting for Finalization of the strategic directions and actions for maternal, child and adolescent mental health care (Cairo, 2010); Expert Review Committee, WHO, South-East Asia Regional Office (SEARO), Meeting on Adolescent Mental Health (New Delhi, India, 2008).